Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 44

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 44
---
 anniversary of the vesting commencement date, and 1/48th of the shares vest on a monthly basis thereafter, in each case subject to Dr. Duffield’s continuous service relationship with the Company through each applicable vesting date. The restricted shares are also subject to certain acceleration of vesting provisions as provided in the applicable named executive officer’s employment agreement.

#### Current Employment Agreements with our NEOs
We have entered into new employment agreements with Dr. Gottesdiener and Dr. Duffield that were effective as of July 2022. We also entered into an employment agreement with Dr. Reine that was effective as of January 2024, pursuant to which we employ Dr. Reine as our Chief Financial Officer.

Each of Dr. Gottesdiener, Dr. Reine and Dr. Duffield are subject to standard confidentiality and nondisclosure, assignment of intellectual property work product and post-termination non-solicitation of employees, consultants and customers covenants and, in certain circumstances, non-competition covenants.

Keith M. Gottesdiener, M.D.

The employment agreement with Dr. Gottesdiener (the “Gottesdiener Employment Agreement”) provides for at-will employment. The agreement also sets forth initial base salary, initial annual target bonus and eligibility to participate in our benefit plans generally. In addition, pursuant to Amendment No. 1 to the Gottesdiener Employment Agreement, Dr. Gottesdiener is entitled to reimbursement for commuting expenses, which include all reasonable

<div align='center'>29</div>

costs for his commute between his family’s residence in New York, New York and our corporate headquarters in Cambridge, Massachusetts.

Pursuant to the Gottesdiener Employment Agreement, in the event Dr. Gottesdiener is terminated by us without “cause” or he resigns for “good reason” (as such terms are defined in the Gottesdiener Employment Agreement), in each case subject to the delivery of and compliance with a fully effective separation agreement that shall include, without limitation, a release of claims, reaffirmation of applicable restrictive covenants and, in the Company’s discretion, a one year non-competition agreement, Dr. Gottesdiener will be entitled to (i) an amount equal to the sum of (A) 12 months of his then-current base salary plus (B) 1.0 times his target annual bonus for the then current year, in each case subject to reductions by